It is also promising when considering the KEYNOTE 28 study [20] results, which suggested a modest, but durable, response with pembrolizumab monotherapy in previously treated PD-L1-positive, ER+/HER2- BC patients. This evidence concerns the gene ERBB2 and breast cancer.